Clinic Features and Outcome of BPD (SGBPD)

Wang Jianhui

Status: Unknown

Conditions: Bronchopulmonary Dysplasia

Study type: Observational

Funder types: Other

Identifiers

NCT04237844

20191112

Details and patient eligibility

About

This study described the perinatal high-risk factors and clinical manifestations of the children, and compared the high-risk factors, clinical manifestations and prognosis of BPD among different clinical subtypes by comparison between groups. BPD grading was performed using the 2018 grading standard to compare the distribution of I/II/III BPD among different groups.

Enrollment: 300 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Premature infants born at <32 weeks of gestational age;
2. hospitalization time ≥ 14 days;
3. The clinical medical records are complete

Exclusion criteria

• • 1) Children with congenital heart, lung malformation and definite chromosomal diseases; 2) children gave up treatment halfway; 3) corrected gestational age 36 weeks before death, the cause of death was confirmed as factors other than respiratory system.

Trial design

300 participants in 5 patient groups

no BPD

Description:

In preterm infants(GA\<32 weeks and hospital day\>14 days )，infants without BPD

classic BPD

Description:

In preterm infants(GA\<32 weeks and hospital day\>14 days )，There are clinical manifestations and imaging evidence of RDS after birth, the condition is not relieved, FiO2 lasts \>25%

BPD after RDS

Description:

In preterm infants(GA\<32 weeks and hospital day\>14 days )，There are clinical manifestations and imaging evidence of RDS after birth. FiO2\<23% within 7 days, and the condition is aggravated to FiO2\>25%.

Delayed BPD

Description:

In preterm infants(GA\<32 weeks and hospital day\>14 days )，There is no RDS performance after birth, FiO2 lasts \<25%

Early, lethal BPD

Description:

In preterm infants(GA\<32 weeks and hospital day\>14 days )，Some infants who die before 36 weeks PMA (between 14 days of postnatal age and 36 weeks) due to persistent parenchymal lung disease and respiratory failure that can not be attributable to other neonatalmorbidities